

AD \_\_\_\_\_

Award Number: DAMD17-00-1-0380

TITLE: The Use of Venezuelan Equine Encephalitis Replicons  
Encoding the Her-2/neu Tumor Associated Antigen for the  
Prevention and Treatment of Breast Cancer

PRINCIPAL INVESTIGATOR: Brian R. Long  
Roland M. Tisch, Ph.D.

CONTRACTING ORGANIZATION: University of North Carolina  
at Chapel Hill  
Chapel Hill, North Carolina 27599-1350

REPORT DATE: May 2001

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are  
those of the author(s) and should not be construed as an official  
Department of the Army position, policy or decision unless so  
designated by other documentation.

20010921 092

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 074-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE May 2001		3. REPORT TYPE AND DATES COVERED Annual Summary (15 Apr 00 - 14 Apr 01)
4. TITLE AND SUBTITLE The Use of Venezuelan Equine Encephalitis Replicons Encoding the Her-2/neu Tumor Associated Antigen for the Prevention and Treatment of Breast Cancer			5. FUNDING NUMBERS DAMD17-00-1-0380	
6. AUTHOR(S) Brian R. Long Roland M. Tisch, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of North Carolina at Chapel Hill Chapel Hill, North Carolina 27599-1350  E-Mail: <a href="mailto:blong@med.unc.edu">blong@med.unc.edu</a>			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)  U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words)				
14. SUBJECT TERMS Breast Cancer				15. NUMBER OF PAGES 7
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

## Table of Contents

• Overview	Pg 1
• Key Accomplishments	Pg 2
• Reportable Outcomes	Pg 2
• Figures	Pg 3
• Summary	Pg 4
• References	Pg 4

## Overview:

During the past year, we have been focusing on the objectives outlined for Specific Aim 1 in our approved statement of work, and have completed an initial experiment related to Specific Aim 2. Testing and packaging of VEE replicon constructs encoding Her-2/neu, IL-12 and IL-18 have been completed. Additionally, a replicon construct encoding murine granulocyte-macrophage colony stimulating factor (mGM-CSF), has been established and tested and a truncated Her-2/neu gene encoding the extracellular and transmembrane domain of the protein is currently being assessed. We are hopeful the reduced size of the Her-2/neu gene will lead to increased levels of RNA and protein expression.

The rat Her-2/neu gene encodes for an 185kDa transmembrane protein. In order that we may have protein to work with experimentally, we have cloned overlapping fragments of the gene into a bacterial expression plasmid. Currently, one protein generated from the bacterial expression system, encompassing parts of the extracellular and transmembrane domains, has been used to demonstrate CD4<sup>+</sup> T helper (Th) cell proliferation (Figure 1). For this experiment, mice were immunized intraperitoneally with 100µg of the protein fragment emulsified in incomplete Freund's adjuvant (IFA). Splenocytes were then recovered and assessed for T cell proliferation by <sup>3</sup>H-thymidine uptake. Both rat HER-2/neu and A2-K<sup>b</sup> transgenic mice showed significant proliferative responses. A second fragment, further spanning the extracellular domain, is in the process of being tested.

We have begun to characterize the CD8<sup>+</sup> T cell response induced by replicons encoding Her-2/neu in both wild type FVB, and in FVB mice transgenic for the rat HER-2/neu gene. We have repeatedly generated significant CTL responses in wild type FVB mice, but CTL reactivity induced in Her-2/neu transgenic mice has to date been limited (Figure 2). The work of Jaffee et al. has demonstrated that Neu-specific T cell responses can be generated in Her-2/neu transgenic mice immunized with recombinant vaccinia virus expressing Neu.<sup>1</sup> Consequently, we are hopeful that the appropriate combination of replicons encoding Her-2/neu as well as key inflammatory cytokines will overcome this element of immune tolerance seen in the transgenic mice.

One experiment has been completed in which both wild type FVB and Her-2/neu transgenic mice were immunized with replicons encoding Her-2/neu, and subsequently challenged with the F-H2N1 tumor cell line (expressing Her-2/neu). Both immunized and unimmunized Her-2/neu transgenic mice exhibited significant tumor growth whereas both groups of wild type mice rejected the tumor. While there was no significant difference in tumor weight from immunized and unimmunized Her-2/neu transgenic mice, decreased vascularity was noted in tumors recovered from the VEE Her-2/neu immunized mice. While we have no evidence that this decreased vascularity may be attributable to the vaccination, we remain optimistic that the correct combination of antigen and cytokine encoding replicons will be effective in inhibiting tumor growth.

Many of the tools are now in place that will allow us to test various antigen and cytokine combinations for optimal CD4<sup>+</sup> Th and CD8<sup>+</sup> CTL reactivity. This will further allow us to establish an effective approach of immunotherapy targeting Her-2/neu for the treatment and prevention of breast adenocarcinoma in transgenic mice.


## Key Accomplishments:

- Completed *in vitro* testing and packaging of the following VEE replicons:
  - Full length Her-2/neu
  - IL-12
  - IL-18
  - mGM-CSF
  - IL-2
- Currently testing truncated Her-2/*neu* replicon encoding the extracellular and transmembrane domains.
- Cloned fragments of the Her-2/*neu* gene into a bacterial expression system and generated recombinant protein.
- Demonstrated CD4<sup>+</sup> Th cell reactivity to one Her-2/*neu* protein fragment, and are in the process of testing a second fragment.
- Repeatedly generated CD8<sup>+</sup> CTL reactivity in wild type FVB mice.
- Completed one tumor challenge experiment in VEE Her-2/*neu* immunized mice.

## Reportable Outcomes:


- None.

# Figures and Tables:



**Figure 1.** Proliferation in response to Her-2/*neu* fragment 4. Fragment 4 encompasses nucleotides 1856 – 2585 spanning part of the extracellular domain, the entire transmembrane domain and a small section of the intracellular domain. Her-2/*neu* transgenic and A2-K<sup>b</sup> transgenic mice were twice immunized intraperitoneally with 100 µg fragment 4 emulsified in IFA. Splenocytes were harvested and incubated with the indicated concentration of recombinant protein and the levels of <sup>3</sup>H-thymidine incorporation were measured. Data represents groups of three mice.

## 5 Hour <sup>51</sup>Cr Release Assay



**Figure 2.** Standard 5 hr chromium release assay for FVB and FVB/*Neu*<sup>+/+</sup> mice immunized with VEE replicons encoding Her-2/*neu* ( $3.0 \times 10^5$  IU) and replicons encoding mGM-CSF ( $3.0 \times 10^4$  IU). Mice were immunized in the footpad 3X at 7 day intervals and sacrificed 3 – 5 days following the final injection. Spleen and popliteal lymph node cell suspensions were stimulated *in vitro* with psorelen inactivated NIH-3T3 cells (H-2<sup>a</sup>) permanently transfected with Her-2/*neu* and B7-1 encoding constructs. Stimulated lymphocytes were incubated with <sup>51</sup>Cr labeled targets in the indicated ratios for 5 hours. 3T3 = non-transfected NIH-3T3 cells. Neu+B7 = NIH-3T3 cells transfected with Her-2/*neu* and B7.1. Data represents groups of 2 mice.

## Summary:

Much of the work described for Specific Aim 1 has now been completed. We have finished the *in vitro* testing and packaging of the replicon constructs described, and have begun work on additional constructs. Progress has been made characterizing the CD8<sup>+</sup> T cell response in both wild type and Her-2/*neu* transgenic mice with generation of consistent CTL activity in the wild type mice. Additionally, we have cloned overlapping fragments of the Her-2/*neu* gene into a bacterial expression system, and demonstrated a proliferative response to one of the recombinant proteins. These fragments will be used to evaluate CD4<sup>+</sup> T helper responses in immunized mice. We believe an immunotherapeutic protocol consisting of the appropriate combination and antigen and cytokine encoding replicons will be useful for overcoming the tolerance associated with the Her-2/*neu* transgenic mice.

In our initial tumor challenge experiment with replicons encoding Her-2/*neu* alone, we failed to mediate rejection of transferred Neu expressing tumors in Her-2/*neu* transgenic mice. Again, we feel it will be a matter of determining the appropriate cytokine encoding constructs for use in our protocol.

## References:

Reilly, R. Todd, Morris B.C. Gottlieb, Anne M. Ercolini, Jean-Pascal H. Machiels, Colin E. Kane, Francesca I. Okoye, William J. Muller, Katherine H. Dixon, and Elizabeth M. Jaffee. (2000). Her-2/*neu* Is a Tumor Rejection Target in Tolerized HER-2/*neu* Transgenic Mice. Cancer Research 60, 3569-3576